Table 1.
Demographic and baseline characteristics.
| 250 nM (n = 3) | 1000 nM (n = 3) | 2500 nM (n = 3) | 10,000 nM (n = 13) | |
|---|---|---|---|---|
| Male (n) | 1 | 0 | 1 | 6 |
| Female (n) | 2 | 3 | 2 | 7 |
| Mean age (years) [SD] | 69.7 [11.9] | 66.7 [13.1] | 66.3 [4.2] | 65.8 [5.9] |
| Median duration of PDAC (months) [IQR] | 14.0 [5.0–17.0] | 6.0 [6.0–7.0] | 6.0 [3.0–6.0] | 6.0 [4.0–9.0] |
| Mean tumor size (mm) [SD] | 47.0 [12.53] | 29.4 [9.54] | 34.0 [17.91] | 42.4 [18.55] |
| Location: n (%) | ||||
| Head | 0 (0.0) | 2 (66.7) | 0 (0.0) | 3 (23.1) |
| Body | 1 (33.3) | 1 (33.3) | 1 (33.3) | 6 (46.2) |
| Tail | 1 (33.3) | 0 (0.0) | 0 (0.0) | 5 (38.5) |
| Other | 1 (33.3) | 0 (0.0) | 2 (66.7) | 1 (7.7) |
| Metastasis: n (%) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 10 (76.9) |
| ECOG PS: n (%) | ||||
| 0 | 3 (100.0) | 3 (100.0) | 2 (66.7) | 12 (92.3) |
| 1 | 0 (0.0) | 0 (0.0) | 1 (33.3) | 1 (7.7) |
| GEM + nab-PTX as a first-line: n (%) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 13 (100.0) |
| Combined S-1 as a second-line: n (%) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 13 (100.0) |
| Baseline mean % positive area for CHST15 (%) [SD] | 13.4 [3.9] | 17.8 [8.8] | 28.7 [11.1] | 17.0a [9.4] |
GEM: gemcitabine, PTX: paclitaxel, SD: Standard Deviation.
a
Mean value of the evaluable population (n = 12).